May be because AD asked them to do

The 10:1 reverse split will bring us to $5, but if the stock is taken down to $1, it means the market cap will be $50M when we have cash around $300M. Even, If we go to $1 after the split then Dinner can buy every stock of AMRN for $50M using the buyback? Its crazy to think about it.

TC1, If Amarin sought an injunction other generics will be scared to fill the void. Look at Oracle that won the copyright infringement case against Rimini Street. Thanks to Du. The other companies like spinnaker and Support Resolution who are in the same business as Rimini Street are scared to work on the copyright protected materials. Similarly, Amarin win against Hikma would scare Reddy ,Teva and others.

https://www.oracle.com/news/announcement/oracle-wins-copyright-case-against-repeat-violator-rimini-street-2023-07-25/

Last month Miranda Du even awarded Oracle's attorneys' fees from Rimini Street. Hope we can claim that as well from Hikma if we win the case. I am sure Du will help us.

https://www.reuters.com/legal/litigation/oracle-wins-585-mln-attorneys-fees-rimini-copyright-case-2024-09-23/

NS - You are correct. The more Hikma delays the case the more they become liable (Assuming AMRN wins the case)

NS, The PBM may argue that this kind of deal making with Pharma companies (including Generics) is to make sure the subscribers get a good rate on the medications. How can one prove that, that is not the case.

Are we supposed to get the BRAVE results posted on the NIH website by end of September? Are there any updates?

I also heard from CNBC Squawk Box this morning that neither of the presidential candidates want FTC to have this much power to go after companies and Lina Khan's days are numbered. These corporations know how to handle and cover up the findings. What a sad state we are in.

Assuming we are status quo in next quarter, Our revenue for the next quarter will be $67.5 minus $15 from China minus 1/3 loss of revenue from PBM. It looks live we will see a loss of $8M next quarter? [(67.5 -15 - 1/3(67.5-15)) = $35 - 43.3 = -8.3]

NS - Not sure if 07/31 update is coincidence or intentional. It goes with the earnings release and the earning release is preponed 2 to 3 days ahead compared to previous years.

NS, This is just my layman guess, Even though the study concluded, the end point could not be reached but the effect of IPE is progressing in the right direction, They may need more money and a longer study to see the effect on AD. I see this conference as a pitch for needing more money, again this is VA. I think, some BP needs to take over AMRN or collaborate on the study as they could be efficient than a VA.

Sleven - Are they saying there is no effect of IPE on triglycerides comparing against placebo. I am surprised at this conclusion.

They could say "Due to additional formalities the approval process is slower than we expected. We will submit for court approval sometime in Q3, 2024 "

May be as part of non public settlement, Hikma buy $50M worth of AMRN shares. It may or may not be a win for both

Zip, Can AMRN make inferior "Authorized Generic" Vascepa to cut cost that equals to the quality of real generics?

DAR53, You are correct but so far the SP this year has been based on the cash on hand and $50M used to BB shares would reduce the cash on hand to $300M and based on how the SP has performed this year, the SP could tract the cash on hand. All good news have been ignored. I understand past performance is not a guarantee of further losses. Lets hope that be the case.

Whal, We are trading at cash value. With cash getting depleted after 50M BB, the market cap should be 305M, meaning the share price should be $0.74/sh. Will this not be the good entry point (after sell, the news event)?

Its a non human (bot) trading on both buy and sell side

Capt - Do you know what plasma EPA level would be considered as ideal? The more the plasma EPA level one wants would cost more but does that provide additional benefits to the patents

5 months back Tanvi did a safety study between IPE and OM3

https://www.linkedin.com/posts/tanvi-patil-pharmd-bcps-dpla-44033827_accpam23-cardiology-fishoil-activity-7130222342558924800-4h5j/?utm_source=share&utm_medium=member_desktop

Marjac, Do you think Amarin should apply for injunction or let Hikma sell the drug and catch them later with treble damages?

Appreciate your input. Thanks

Currently we have recordings starting 04/01 and before. I am guessing the 04/02 recordings will be loaded by the end of today.

https://cafc.uscourts.gov/home/oral-argument/listen-to-oral-arguments/

Even though its one of the lowest selling drugs its sucking up profits from other drugs they sell. They will feel even more pressured if China comes online as the raw material cost could go up as more demand around the world comes online. Just my thought. If next month judgement comes in favor of AMRN, Its not worth having this drug on their list as they may be liable for more damages in the future. Under these circumstances, Reddy would settle.

Thanks Capt for your dedicated analytics work. Looking at the data, it looks like the use of VAZKEPA/ Omacor market is growing and VAZKEPA is able to get the growth portion of this addressable market. The one year drop of Omacor was ~10,000() cap where as VAZKEPA grew by ~100,000 cap. We still have not made a big tent in taking the market share from Omacor. When did England stop Omacor reimbursement? Is it starting this calendar year? If 'Yes', we should see a jump in VAZKEPA sales. Also, I am not sure if VAZKEPA(with reimbursement) is cheaper than Omacor (without reimbursement).

AI is block chain 2.0. It requires a lot of processing power just not to build the LLM but for systems to use them. MSFT implemented co-pilot on Azure but one cannot ask AI to do anything for them on the cloud, still one is bound to security and governance rules. Also, companies cannot use patients health info to build LLM as its HIPAA violation. AI use is limited and its just a flashy object.

JR - Changing the narrative and sales ramp up can only be done with BP, at least a path has been laid to a BP acquisition, I think. Assuming $200M additional revenue and 3x multiple, I see $3B acquisition without considering EU and ROW. Hope similar path can be laid in EU and ROW to increase value.

DAR53 - Assuming half of 5.32M beneficiaries get V (2.5M approx) and at $80 per 120 cap, will the revenue increase be at least 200M per quarter as some point. Is my math correct?

That will happen when super 7 is not super 7 anymore.

Just a contrarian view. If vascepa did not provide meaningful MITIGATE results plus if Amarin provided Vascepa to KP cheaper than Lovaza, KP would prescribe Vascepa as both drugs are ineffective against CVD. So, We cannot assume the results are somewhat positive.

My hope is that we get a positive result from MITIGATE.

I know, I was sarcastic. One IT person can do the job to remove him in both the domains (eu % us) and apparently it looks like EU has a different team to manage web. Looking at other departments in EU, I see a lot of duplication. Why in the world, we need a VP Human Resources, Head of Digital in EU. It all should be one and can be managed from anywhere. Consolidation could eliminate overhead cost.

He is still heading Europe
https://www.amarincorp.eu/about-us/executive-team

Curious! Why are they selling 0.5g when they are already selling Vascepa equivalent of 1g. Is it to help the customers on the cost side?

Trying to execute 200 share @ $1.53 and its not executing for 20 minutes. Wondering if no one want to sell at this price but someone is ready to sell @ $1.535. It looked like bots trading these to cap the price

It would be the year of efficiency, meaning cost savings/cost cutting and there by the earnings would at least be 100% more from the last quarter to the next and so on. It would lead to increase in share price. I think by the end of the year AD will break even with his AMRN investment.

Robin, Board is saying that they are already well compensated with a lot of stock options and they don't have to buy more to prove that they have vested interest in the company. I agree with you, they need to buy in open market to prove that.

I did the same and I couldn't change my vote on the White (I left it 'For' on this card). When I got my Blue card (I again voted again as 'For' on this card, even though it said that I already voted). I was told the latest timestamped vote is what icounts. Correct me if I am wrong.

I was told the same regarding my 401k with Fidelity and they said the proxy material should be available here (https://statements.fidelity.com/ftgw/fbc/ofstatements/getProxyMaterials)

$13 to $15

It could be legit. I called them and they were able to pull my last name based on my home phone #. They asked me to vote the white card.

I think AD took the position around $4/share. So, he could be valuing the company at 4*4.9 = $19.6/share

Voting Question: I have Fidelity account and several accounts in Ameritrade that holds AMRN shares. How many control # will I get for voting. Is it one per brokerage or one per account per brokerage?